p16 阳性口咽癌术后辅助治疗延迟的影响：一项回顾性分析。
Impact of delayed adjuvant therapy after surgery in p16 positive oropharyngeal cancer: a retrospective analysis.
机构信息
Department of Otorhinolaryngology, Head and Neck Surgery, Friedrich Alexander University of Erlangen-Nuremberg, Germany.
出版信息
Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1211-1218. doi: 10.26355/eurrev_202002_20173.
OBJECTIVE
This study aimed to clarify the impact of delayed adjuvant therapy on the outcome of HPV associated oropharyngeal squamous cell carcinoma (HPV-OPSCC).
PATIENTS AND METHODS
A total of 157 patients with HPV-OPSCC treated by surgery and adjuvant radiotherapy or chemoradiation therapy were analyzed retrospectively. We divided participants into two groups implementing adjuvant therapy within or after 50 days. Primary endpoints were the rates of locoregional recurrence and distant metastases, overall survival, and disease-specific survival.
RESULTS
Adjuvant treatment began within 50 days (average: 38.8 days) in 79 cases compared to 78 cases after 50 days (average: 71.5 days). Five-year overall survival was 85.7% and 87.4% (p=0.588), the rates of local and regional recurrence were 3.8% and 6.4% (p=0.455) and of distant metastases 5.1% and 9% (p=0.369) implementing adjuvant treatment within or later than 50 days, respectively.
CONCLUSIONS
These results suggest that adjuvant therapy initiated later than seven weeks after primary ablative surgery may still be effective HPV-OPSCC.
目的
本研究旨在阐明延迟辅助治疗对 HPV 相关口咽鳞状细胞癌（HPV-OPSCC）患者结局的影响。
方法
回顾性分析了 157 例接受手术和辅助放疗或放化疗治疗的 HPV-OPSCC 患者。我们将参与者分为两组，分别在 50 天内和 50 天后进行辅助治疗。主要终点是局部区域复发和远处转移、总生存率和疾病特异性生存率的发生率。
结果
79 例患者在 50 天内（平均 38.8 天）开始辅助治疗，78 例患者在 50 天后（平均 71.5 天）开始辅助治疗。5 年总生存率分别为 85.7%和 87.4%（p=0.588），局部和区域复发率分别为 3.8%和 6.4%（p=0.455），远处转移率分别为 5.1%和 9%（p=0.369）。
结论
这些结果表明，在原发性消融手术后 7 周以上开始辅助治疗可能对 HPV-OPSCC 仍然有效。
Zotero 插件